“…FGF21 is a hormone that regulates glucose–lipid metabolic pathways, including stimulating the oxidation of fatty acids, production of ketone bodies, inhibition of lipogenesis, glucose uptake, amino acid transport, and energy expenditure [ 4 , 5 , 6 ]. Thus, FGF21 is involved in many metabolic diseases, such as obesity, diabetes, and non-alcoholic fatty liver [ 7 , 8 , 9 ], making it a promising therapeutic target for these metabolic diseases. Actually, FGF21 analogs LY2405319, PF-05231023, etc., were proven to be effective therapeutic agents in obesity, type 2 diabetes mellitus (T2DM), non-alcohol fatty liver disease (NAFLD) and cholestatic liver disease [ 10 , 11 ].…”